Control Bionics Limited (ASX:CBL)

Market Cap	30.07M +96.3%
Revenue (ttm)	6.07M +14.9%
Net Income	-6.50M
EPS	-0.02
Shares Out	411.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,998
Open	0.0730
Previous Close	0.0700
Day's Range	0.0730 - 0.0730
52-Week Range	0.0320 - 0.0950
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 31, 2026

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyogr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In fiscal year 2025, Control Bionics's revenue was 6.14 million, an increase of 14.84% compared to the previous year's 5.35 million. Losses were -6.11 million, 3.30% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error